Michael Herold
About
Michael Herold is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology.
According to data from OpenAlex, Michael Herold has authored 134 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Pathology and Forensic Medicine, 32 papers in Genetics and 30 papers in Oncology. Recurrent topics in Michael Herold's work include Lymphoma Diagnosis and Treatment (59 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Viral-associated cancers and disorders (21 papers). Michael Herold is often cited by papers focused on Lymphoma Diagnosis and Treatment (59 papers), Chronic Lymphocytic Leukemia Research (30 papers) and Viral-associated cancers and disorders (21 papers). Michael Herold collaborates with scholars based in Germany, United States and Switzerland. Michael Herold's co-authors include Wolfgang Hiddemann, M. Schwoerer, Robert Marcus, J. Gmeiner, John F. Seymour, Tilmann Walk, Hennicke Kamp, W. Mellert, Christiane Gatz and Günter Fingerle‐Rowson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Michael Herold
129 papers receiving 3.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Michael Herold Germany | 30 | 1.7k | 1.2k | 945 | 667 | 399 | 134 | 3.3k | ||
| Anthony M. Magliocco Canada | 38 | 407 0.2× | 1.8k 1.4× | 388 0.4× | 1.3k 2.0× | 307 0.8× | 136 | 4.2k | ||
| Jonathan M. Irish United States | 34 | 743 0.4× | 1.5k 1.2× | 634 0.7× | 2.6k 3.8× | 1.8k 4.6× | 109 | 5.2k | ||
| Kai Fu United States | 31 | 1.9k 1.1× | 1.4k 1.1× | 866 0.9× | 1.1k 1.6× | 425 1.1× | 152 | 3.8k | ||
| James C. Cusack United States | 35 | 368 0.2× | 2.7k 2.1× | 133 0.1× | 2.6k 4.0× | 567 1.4× | 89 | 5.1k | ||
| Phyu P. Aung United States | 33 | 554 0.3× | 1.8k 1.4× | 118 0.1× | 1.5k 2.2× | 570 1.4× | 188 | 4.0k | ||
| Xiao‐Feng Sun Sweden | 44 | 975 0.6× | 1.9k 1.5× | 148 0.2× | 3.2k 4.8× | 392 1.0× | 237 | 6.3k | ||
| Christina M. Annunziata United States | 37 | 551 0.3× | 2.6k 2.1× | 140 0.1× | 2.5k 3.8× | 1.2k 2.9× | 155 | 5.4k | ||
| Jianxiang Wang China | 42 | 319 0.2× | 2.1k 1.7× | 1.1k 1.2× | 3.8k 5.6× | 1.1k 2.8× | 415 | 7.7k | ||
| Ying Yang China | 41 | 432 0.3× | 1.7k 1.3× | 240 0.3× | 2.2k 3.2× | 502 1.3× | 136 | 5.1k | ||
| Yun Dai United States | 49 | 524 0.3× | 2.2k 1.8× | 557 0.6× | 5.5k 8.2× | 789 2.0× | 202 | 7.8k |
Countries citing papers authored by Michael Herold
Since
Specialization
Citations
This map shows the geographic impact of Michael Herold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Herold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Herold more than expected).
Fields of papers citing papers by Michael Herold
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael Herold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Herold. The network helps show where Michael Herold may publish in the future.
Co-authorship network of co-authors of Michael Herold
This figure shows the co-authorship network connecting the top 25 collaborators of Michael Herold. A scholar is included among the top collaborators of Michael Herold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Herold. Michael Herold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Birk, Barbara, Philipp Ternes, Franziska Maria Zickgraf, et al.. (2023). Application of high throughput in vitro metabolomics for hepatotoxicity mode of action characterization and mechanistic-anchored point of departure derivation: a case study with nitrofurantoin. Archives of Toxicology. 97(11). 2903–2917.
2.
Kostakoğlu, Lale, Maurizio Martelli, Laurie H. Sehn, et al.. (2023). A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials. SHILAP Revista de lepidopterología. 4(4). 1042–1051.
3.
Birk, Barbara, Philipp Ternes, Volker Haake, et al.. (2023). A high-throughput metabolomics in vitro platform for the characterization of hepatotoxicity. Cell Biology and Toxicology. 39(6). 2899–2917.
4.
Townsend, William, Wolfgang Hiddemann, Christian Buske, et al.. (2023). Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. HemaSphere. 7(7). e919–e919.
5.
Herold, Michael, et al.. (2022). Inequalities for Women in Science, Technology and Innovation. Zenodo (CERN European Organization for Nuclear Research). 5(1). pp86–96.
6.
Casulo, Carla, Jesse G. Dixon, Fang‐Shu Ou, et al.. (2021). Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. Blood Advances. 5(6). 1737–1745.
7.
Birk, Barbara, Volker Haake, Saskia Sperber, et al.. (2021). Use of in vitro metabolomics in NRK cells to help predicting nephrotoxicity and differentiating the MoA of nephrotoxicants. Toxicology Letters. 353. 43–59.
8.
Wilhelm, Christian, Roland Moll, Jörg Jäkel, et al.. (2019). Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial. Journal of Cancer Research and Clinical Oncology. 145(8). 2149–2156.
9.
Hiddemann, Wolfgang, Anna Maria Barbui, Miguel Canales, et al.. (2018). Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. Journal of Clinical Oncology. 36(23). 2395–2404.
10.
Pott, Christiane, Eva Hoster, Michael Unterhalt, et al.. (2018). Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients. Blood. 132(Supplement 1). 396–396.
11.
Kaiser, Clemens G., Michael Herold, Pascal Baltzer, et al.. (2017). Prognostic Value of "Prepectoral Edema" in MR-mammography. Anticancer Research. 37(4). 1989–1995.
12.
Hiddemann, Wolfgang, Anna Maria Barbui, Miguel Canales, et al.. (2017). Immunochemotherapy With Obinutuzumab Or Rituximab In Previously Untreated Follicular Lymphoma In The Randomized Phase III Gallium Study: Analysis By Chemotherapy Regimen. Haematologica.
13.
Ramı́rez, Tzutzuy, Alexander Strigun, Erik Peter, et al.. (2017). Prediction of liver toxicity and mode of action using metabolomics in vitro in HepG2 cells. Archives of Toxicology. 92(2). 893–906.
14.
Fabian, Eric, Natalie Bordag, Michael Herold, et al.. (2016). Metabolite profiles of rats in repeated dose toxicological studies after oral and inhalative exposure. Toxicology Letters. 255. 11–23.
15.
Fleury, Isabelle, Sylvie Chevret, Michael Pfreundschuh, et al.. (2015). Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Annals of Oncology. 27(3). 390–397.
16.
Herold, Michael, Antje Haas, Stefanie Srock, et al.. (2007). Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology. 25(15). 1986–1992.
17.
Hopfinger, Georg, Elisabeth Koller, Barbara Schmitt, et al.. (2003). T-PLL-1 protocol of the German CLL study group (GCLLSG) - a prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation as first-line treatment in T-PLL.. mediaTUM (Technical University of Munich).
18.
Herold, Michael, et al.. (1997). Bendamustine, Methotrexate, Mitoxantrone, and Prednisolone (BMMP) for the Treatment of Relapsed or Refractory High-Grade Non-Hodgkin’s Lymphoma. Oncology Research and Treatment. 20(5). 406–408.
19.
Heim, Manfred, W. Queißer, Martin Pecherstorfer, et al.. (1995). Prospective Randomized Trial of Dichloromethylene Bisphosphonate (Clodronate) in Patients with Multiple Myeloma Requiring Treatment. A Multicenter Study. Oncology Research and Treatment. 18(5). 439–448.
20.
Georges, George E. & Michael Herold. (1957). Effets de la 5 hydroxytryptamine sur la motilité intestinale chez le lapin in vivo.. Comptes rendus des séances de la Société de biologie et de ses filiales. 151(1).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Anthony M. Magliocco Breakdown of academic impact, for papers by Jonathan M. Irish Breakdown of academic impact, for papers by Kai Fu Breakdown of academic impact, for papers by James C. Cusack Breakdown of academic impact, for papers by Phyu P. Aung Breakdown of academic impact, for papers by Xiao‐Feng Sun Breakdown of academic impact, for papers by Christina M. Annunziata Breakdown of academic impact, for papers by Jianxiang Wang Breakdown of academic impact, for papers by Ying Yang Breakdown of academic impact, for papers by Yun Dai